Increased expression of PPARβ/δ and Glutaminase, (GLS1) were detected in human HCC that acquired resistance to sorafenib, while pharmacological targeting of PPARβ/δ sensitized HCC cells to sorafenib in vitro and in xenograft models. The gene discussed is GLS; the disease is hepatocellular carcinoma.